期刊文献+

糖皮质激素在系统性红斑狼疮患者合理应用的专家共识 被引量:45

原文传递
导出
摘要 糖皮质激素(以下简称激素)在我国应用广泛,但存在临床使用不合理现象。使用不当,既包括使用过度,即在不应该使用激素时使用;也包括使用不足,即在应该使用激素时未用,或者在应该使用大剂量激素时使用小剂量。无论是使用过度,还是使用不足,均会给患者的健康造成损害。我国系统性红斑狼疮(SLE)的患病率较高,大样本的一次性调查(超过3万人)显示,我国SLE患病率为70/10万人,妇女中则高达113/10万人[1]。不同医生使用激素治疗SLE存在差异,因此亟需规范激素在SLE中的应用,根据不同病情,尽量制定简单、规范、合理的激素应用原则,使更多患者获益。
出处 《中华内科杂志》 CAS CSCD 北大核心 2014年第6期502-504,共3页 Chinese Journal of Internal Medicine
  • 相关文献

参考文献14

  • 1系统性红斑狼疮诊断及治疗指南[J].中华风湿病学杂志,2010,14(5):342-346. 被引量:560
  • 2van der Goes MC,Jacobs JW,Boers M,et al.Monitoring adverse events of low-dose glucocorticoid therapy:EULAR recommendations for clinical trials and daily practice[J].Ann Rheum Dis,2010,69:1913-1919.
  • 3Duru N,van der Goes MC,Jacobs JW,et al.EULAR evidencebased and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases[J].Ann Rheum Dis,2013,72:1905-1913.
  • 4Hahn BH,McMahon MA,Wilkinson A,et al.American College of Rheumatology guidelines for screening,treatment,and management of lupus nephritis[J].Arthritis Care Res (Hoboken),2012,64:797-808.
  • 5陈华,张文.糖皮质激素在系统性红斑狼疮治疗中的应用[J].内科理论与实践,2008,3(3):175-179. 被引量:15
  • 6Manson JJ,Rahman A.Systemic lupus erythematosus[J].Orphanet J Rare Dis,2006,1:6.
  • 7Walling HW,Sontheimer RD.Cutaneous lupus erythematosus:issues in diagnosis and treatment[J].Am J Clin Dermatol,2009,10:365-381.
  • 8徐传辉,栗占国.系统性红斑狼疮的循证医学治疗[J].临床内科杂志,2011,28(11):729-731. 被引量:5
  • 9Boumpas DT,Austin HA 3rd,Vaughn EM,et al.Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis[J].Lancet,1992,340:741-745.
  • 10Bertsias GK,Tektonidou M,Amoura Z,et al.Joint European League Against Rheumatism and European Renal AssociationEuropean Dialysis and Transplant Association (EULAR/ERAEDTA) recommendations for the management of adult and paediatric lupus nephritis[J].Ann Rheum Dis,2012,71:1771-1782.

二级参考文献14

  • 1Parker B,Bruce I.High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus.Lupus,2007,16:387-393.
  • 2Ruiz-Irastorza G,Ramos-Casals M,Brito-Zeron P,et al.Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus:a systematic review.Annals of the Rheumatic Diseases,2010,69:20-28.
  • 3Austin HA,Klippel JH,Balow JE,et al.Therapy of Lupus Nephritis.New England Journal of Medicine,1986,314:614-619.
  • 4Houssiau F.Cyclophosphamide in lupus nephritis.Lupus,2005,14:53.
  • 5Appel GB,Contreras G,Dooley MA,et al.Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis.Journal of the American Society of Nephrology,2009,20:1103-1112.
  • 6Ginzler EM,Wofsy D,Isenberg D,et al.Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis:Findings in a multicenter,prospective,randomized,open (O) \ label,parallel (O) \ group clinical trial.Arthritis & Rheumatism,2010,62:211-221.
  • 7Bertsias G,loannidis J,Boletis J,et al.EULAR recommendations for the management of systemic lupus erythematosus.Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics.Annals of the Rheumatic Diseases,2008,67:195.
  • 8Hahn BH.Targeted therapies in systemic lupus erythematosus:successes,failures and future.Annals of the Rheumatic Diseases,2011,70(Suppl 1):S64.
  • 9Navarra SV,Guzm" (Φ) n RM,Gallacher AE,et al.Efficacy and safety of belimumab in patients with active systemic lupus erythematosus:a randomised,placebo-controlled,phase 3 trial.The Lancet,2011.
  • 10Sidiropoulos P,Boumpas D.Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients.Lupus,2004,13:391.

共引文献576

同被引文献438

引证文献45

二级引证文献711

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部